RE:RE:RE:RE:RE:RE:Review of MarathonWhile we don't know the current cash level, it is likely at least $17 million. But it is hard to see a way THTX gets back to $20 million by 10/31 from normal operations outside of some really, really creative financing of marketing rights acquisition.
So, it is more likely they get there via upfront cash in a partnership deal, an equity stake being taken in THTX by another drug company, raising some money through the ATM or a stock sale after some good preliminary results from the restarted TH-1902 trial. Marathon likely knows everything the THTX board knows so I suspect there is a reason they have treated THTX with kid gloves. But if THTX cannot deliver whatever they may have in front of them then I would not count on Marathon continuing to be kind to THTX. It would all likely depend on how Marathon views the prospects for their warrants at that time. If the preliminary TH-1902 results look good, I would expect Marathon to continue being nice to THTX.
palinc2000 wrote: What do Paul and Marathon know ?
1- Amount of liquidity as of yesterday...Over 15 million but under 20 million .... They know the exact amount but we dont know...Is it 18 million and thus making 15 million minimum relatively safe or is it 16 million which is of course riskier
2- June and July revenues if the CFO is able to figure out sales in real time
3- Current cash flow projections for the next 3 months based on budgeted sales and expense reductions
4- Status of discussions if any with possible partners in Nash and Oncology
5-Status of discussions if any for the addition of a new product to be commercialized by THTX sales team
What they DONT know!
1-If Phase 1 will deliver positive results
Conclusion
Execution in sales of products and trajectory and timing of expense reductions are the only life savers in the near term and it would help if the Company was more transparent in the near term and provide updates at least on a monthly basis starting August 31 st